Wegovy®

FDA-approved · Cash-pay · Ships to your door

Wegovy®

Lose weight with the FDA-approved semaglutide pen. Activates GLP-1, the gut hormone that curbs appetite.

Starting at

$499first month

Start your visit

Nothing is charged until a clinician prescribes.

  • FDA-approved for weight management
  • Weekly injection from a single-dose pen
  • Same price at every dose, cancel anytime
  • Cash-pay only; not billed to insurance
US-licensed pharmacyFSA & HSA eligible

The easiest way to find out is to start. Our US-licensed provider partners review a short online intake — usually just a few minutes — and determine what's right for you on an individual basis, based on your health history and goals. There's no cost to find out and no obligation.

Yes. Shipping is always free, and every order arrives in plain, unmarked packaging from a US-licensed pharmacy — no one needs to know what's inside. Most orders arrive within about a week of approval.

Yes. Pallas is a cash-pay medical service, and we provide an itemized receipt for your visit and prescription that you can submit to your FSA or HSA. Most plans treat prescription medications and telehealth visits as eligible expenses — your plan administrator can confirm what applies to you.

About

What is Wegovy®?

Wegovy® is the FDA-approved semaglutide product from Novo Nordisk A/S, indicated for chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbidity. It's a once-weekly subcutaneous injection that works by mimicking the body's GLP-1 hormone — reducing appetite and slowing gastric emptying.

Pallas dispenses Wegovy® through US-licensed pharmacies on a cash-pay basis. Insurance routing is not currently supported. Eligibility is determined by a licensed clinician based on your intake and clinical history.

Pivotal trial · STEP-1

Participants on Wegovy® at 2.4 mg weekly lost an average of 14.9% of body weight at 68 weeks alongside lifestyle intervention.

Source: New England Journal of Medicine, 2021. Outcome reflects the cited trial of the FDA-approved product and the conditions studied. Individual results may differ.

Dosing

Dosing & schedule

Wegovy® follows a 16-week dose-escalation schedule designed to minimize side effects as your body adjusts. Your clinician may modify the cadence based on your tolerability.

  • Weeks 1–40.25 mg once weekly — starting dose
  • Weeks 5–80.5 mg once weekly
  • Weeks 9–121.0 mg once weekly
  • Weeks 13–161.7 mg once weekly
  • Week 17+2.4 mg once weekly — maintenance dose

Common questions

The easiest way to find out is to start. Our US-licensed provider partners review a short online intake — usually just a few minutes — and determine what's right for you on an individual basis, based on your health history and goals. There's no cost to find out and no obligation.

Yes. Shipping is always free, and every order arrives in plain, unmarked packaging from a US-licensed pharmacy — no one needs to know what's inside. Most orders arrive within about a week of approval.

Yes. Pallas is a cash-pay medical service, and we provide an itemized receipt for your visit and prescription that you can submit to your FSA or HSA. Most plans treat prescription medications and telehealth visits as eligible expenses — your plan administrator can confirm what applies to you.

We'll make it right. Pallas includes unlimited customer support — if anything's off with your shipment, or you simply have a question about your treatment, our support team and your care team are a message away, as often as you need, at no extra cost.

Pallas is cash-pay and doesn't bill insurance directly — that keeps your pricing simple and predictable. But because you receive the genuine, FDA-approved product with an itemized receipt, some patients choose to submit a claim to their insurer afterward for possible out-of-network reimbursement. Whether it's reimbursed is up to your individual plan.

Wegovy® is the brand name for the FDA-approved semaglutide injection manufactured by Novo Nordisk for chronic weight management. It's a once-weekly subcutaneous injection delivered via a single-dose pen.

All three are FDA-approved GLP-1 medications, but with different active ingredients, indications, and dosing. Wegovy® and Ozempic® both contain semaglutide (made by Novo Nordisk), but Wegovy® is FDA-approved for weight management while Ozempic® is FDA-approved for type 2 diabetes. Zepbound® contains a different molecule — tirzepatide, made by Eli Lilly — and is FDA-approved for weight management.

The Wegovy® pen is $499 for your first month, then $599 every 4 weeks, charged only once a clinician prescribes, then renewing every 4 weeks until you cancel, with no insurance routing. Other terms are quarterly ($1,737 every 12 weeks, $579/mo average). The price is the same at every dose, and each charge covers a supply shipped directly from a US-licensed pharmacy. Pricing reflects pharmacy cash-pay rates and may change.

Yes — no contracts and no lock-in. You can pause or cancel your plan anytime, right from your patient portal.

Wegovy®

$499 first month

  • Cancel anytime
  • Free expedited shipping
  • FSA & HSA eligible
  • Care-team messaging included
Wegovy®